Is MOTS-c Legal in the US in 2026?
MOTS-c is not FDA-approved and is not a controlled substance. Its legal status for compounding and clinical use is actively evolving. Here is a plain-language breakdown of where things stand.
MOTS-c Status Summary (2026)
| Question | Answer |
|---|---|
| FDA approved? | No |
| Controlled substance (DEA scheduled)? | No |
| Legal to possess? | Not explicitly prohibited |
| Legal to prescribe? | Gray area — physician discretion |
| Compounding pharmacy eligible? | Restricted; limited availability |
| Clinical trials status? | Phase I/II; see below |
MOTS-c Clinical Trial Status (2026)
MOTS-c is a mitochondria-derived peptide (MDPs) that has attracted significant research interest for metabolic health and longevity. Several clinical investigations are underway or recently completed:
- Phase I safety trials have been conducted assessing MOTS-c tolerability in healthy adult volunteers
- Phase II studies examining metabolic outcomes (insulin sensitivity, body composition) are ongoing as of early 2026
- Registration studies are visible on ClinicalTrials.gov; search "MOTS-c" for current status
Important: Active clinical trials do not mean MOTS-c is FDA-approved. Investigational use is restricted to trial participants under institutional oversight.
MOTS-c FDA Approval Status (2026)
MOTS-c has no FDA approval as of 2026. It is not an approved drug, biologics license application (BLA), or new drug application (NDA) holder. This means:
- No manufacturer can legally market MOTS-c as a prescription drug
- Insurance will not cover it
- It cannot be advertised with drug efficacy claims
However, lack of approval does not mean possession is criminal. The legal framework that restricts MOTS-c is primarily regulatory (compounding rules, pharmacy laws) rather than criminal statutes.
Can You Get MOTS-c From a US Compounding Pharmacy?
With increasing difficulty. The FDA's scrutiny of peptides used in compounding has intensified since 2022. MOTS-c specifically:
- Is not on the FDA's "Category 1" list of bulk substances that may be compounded
- Has not been definitively placed on the "Category 2" prohibited list (as of early 2026)
- Occupies a nominally gray area where some 503A compounding pharmacies continue to prepare it
In practice, availability varies significantly by pharmacy. Clinics specializing in peptide therapy are the most reliable source of current availability information.
Is MOTS-c Legal to Import?
Importing MOTS-c from overseas suppliers (including research chemical vendors) for human use is not authorized under FDA regulations. The FDA can seize shipments at the border under FDCA authority. Enforcement discretion exists for small personal quantities, but there is no guarantee.
Research chemical vendors based overseas often label MOTS-c "not for human use" — this disclaimer does not create legal protection for the buyer.
How MOTS-c Differs From Other Peptides Legally
Unlike sermorelin (a withdrawn FDA drug that retains compounding eligibility) or tesamorelin (an approved drug with narrow indication), MOTS-c has never had FDA approval and was identified as a novel peptide only relatively recently (first described in human cells in 2015). This makes its regulatory history shorter and its compounding pathway less established.
What to Do If You Want to Try MOTS-c
The safest legal pathway:
- Consult a physician who specializes in peptide therapy or functional/anti-aging medicine
- Discuss whether MOTS-c is appropriate for your goals and health status
- If prescribed, obtain it from an accredited US compounding pharmacy under physician oversight
Use our clinic directory to find a verified provider.
Frequently Asked Questions
Is MOTS-c legal?
In the US, MOTS-c is not a controlled substance and not explicitly illegal to possess. However, it cannot be legally marketed as a drug, and its availability through licensed compounding pharmacies is limited. The most compliant path is via physician prescription from a licensed compounding pharmacy.
Is MOTS-c FDA approved?
No. As of 2026, MOTS-c has no FDA approval for any indication. Clinical trials are ongoing, but approval is not imminent.
What are the MOTS-c clinical trials in 2026?
Multiple Phase I and Phase II trials are underway investigating MOTS-c's effects on metabolic function, aging biomarkers, and insulin sensitivity. These are the primary source of human safety and efficacy data. Check ClinicalTrials.gov for current enrollment status.
Can a doctor prescribe MOTS-c?
A physician can prescribe MOTS-c off-label if an accredited compounding pharmacy is willing to prepare it. Whether they will and whether this is advisable depends on the individual clinical situation and the pharmacy's current formulary.
Is MOTS-c safe?
Human safety data is limited compared to established peptides. Phase I trial data suggests reasonable tolerability, but long-term safety in healthy adults is not well characterized. This is a key reason physician supervision is important.
This information is for educational purposes only and does not constitute legal or medical advice. Regulatory status can change. Consult a licensed healthcare provider and attorney for guidance specific to your situation.
